title: Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy.
abstract: An exploration of the immunotherapeutic potential of the pan-Bcl-2 inhibitor GX15-070 (GX15) has revealed that early-activated T cells derived from human peripheral blood are more sensitive to GX15 than are prolonged-activated T cells. Furthermore, non-memory and regulatory T cells also exhibit higher sensitivity to GX15. The implication of these prior findings suggests that GX15 may enhance the efficacy of immunotherapies in clinical settings.
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Kim
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schlom
keywords: T lymphocytes; combination immunotherapy; pan-Bcl-2 inhibitor; regulatory T cells
references.citation: Cancer Res. 2012 Jul 15;72(14):3439-44
references.pmid: 22761338
references.citation: Expert Opin Investig Drugs. 2012 Mar;21(3):363-73
references.pmid: 22324354
references.citation: Int J Cancer. 2010 Oct 1;127(7):1603-13
references.pmid: 20091862
references.citation: J Exp Med. 2007 Jul 9;204(7):1665-75
references.pmid: 17591857
references.citation: BMC Med Genomics. 2008 Oct 23;1:53
references.pmid: 18947405
references.citation: J Immunol. 2014 Mar 15;192(6):2622-33
references.pmid: 24516200
references.citation: Semin Oncol. 2012 Jun;39(3):323-39
references.pmid: 22595055
references.citation: Exp Biol Med (Maywood). 2013 Feb;238(2):248-56
references.pmid: 23576806
references.citation: J Immunol. 2011 May 15;186(10):5729-37
references.pmid: 21451108
references.citation: Cancer Res. 2010 Jun 15;70(12):4850-8
references.pmid: 20501849